Figures from the publication by Davis and collaborators. DUF1220 dosage is distributed in patients with autism spectrum disorders (ASD) in an almost Gaussian fashion, which is not much different from what is expected in the general population. However, there is a linear correlation between DUF1220 dosage and various ASD-related features including measures for social deficits, communicative impairments, and repetitive behaviors (figure adapted from the publication by Davis and collaborators under a Creative Commons License).

Ingo Helbig

Child Neurology Fellow and epilepsy genetics researcher at the Children’s Hospital of Philadelphia (CHOP), USA and Department of Neuropediatrics, Kiel, Germany

Facebook Twitter 

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.